Albert Bourla, CEO of drugmaker Pfizer, has tested positive for Covid-19 and has “very mild symptoms,” he said in a tweet de luni.
“I would like to let you know that I have tested positive for #COVID19,” Bourla wrote. “I am thankful to have received four doses of the Pfizer-BioNTech vaccine, and I am feeling well while experiencing very mild symptoms. I am isolating and have started a course of Paxlovid.”
Pfizer to acquire antiviral biopharma with HQ in Durham for up to $525M
He said that he is “confident I will have a speedy recovery,” due to how far the world has come in efforts to battle the coronavirus and expressed gratitude for his colleagues who worked to make vaccines and treatments available.
Pfizer shared the same information in a company declaraţie.
Pfizer’s vaccine was the first Covid-19 vaccine in the United States to receive US Food and Drug Administration autorizație de utilizare de urgență in December 2020. Since then, it has received aprobare deplină for use in people age 16 and up and is authorized for other ages groups down to copiilor as young as six months. It is also authorized as a rapel dose for those age 5 and older and as a second booster dose for adults age 50 and older or people who are immunocompromised.
Pfizer is also working on updated shots to target the Omicron variant, with the company saying they could be available in the early fall depending on signoff by federal officials.
Pfizer to buy Global Blood Therapeutics in $5.4 billion deal
Bourla shared information about the company’s oral antiviral Covid-19 treatment, Paxlovid, in his messages on Twitter.
Paxlovid was granted autorizație de utilizare de urgență by the FDA in December 2021. Paxlovid can be used for treatment of mild to moderate Covid-19 in people age 12 and up and who weight at least 88 pounds and are at risk of severe disease.
President Joe Biden took Paxlovid when he testat pozitiv for Covid-19 last month.
The-CNN-Wire™ și © 2022 Cable News Network, Inc., o companie WarnerMedia. Toate drepturile rezervate.
US moves to broaden access to Pfizer antiviral drug for treatment of COVID
